Skip to main content
Premium Trial:

Request an Annual Quote

IsoPlexis, Institute for Systems Biology Partner to Identify COVID-19 Immune Mechanisms

NEW YORK – IsoPlexis has partnered with the Institute for Systems Biology (ISB) to map functional immune response to COVID-19 at the single-cell level.

The group will use IsoPlexis' single-cell functional platform to analyze immune cells from individuals who have been diagnosed or recovered from COVID-19. The team aims to examine a variety of immune cell types — including various T cells and myeloid cells — to put together a map of the overall response.

"Critical information from all aspects of the immune response will be key in understanding how to fight [COVID-19] and address complications," James Health, president of the ISB, said in a statement. "Functional phenotypes of each immune cell, using IsoPlexis' system, will be a cornerstone of the understanding of this immune response in affected patients."  

Financial details of the collaboration were not disclosed.

"Through our unique functional analysis of each cell, we can unlock further understanding of how COVID-19 interacts with the immune system," Sean Mackay, CEO and cofounder of IsoPlexis, said in a statement. "Cellular immune signatures based on cytokines may be key in understanding and predicting response, and also how to mitigate disease progression."

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.